Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Alexza Pharmaceuticals Inc. | d75966exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2010 (September 7, 2010)
ALEXZA PHARMACEUTICALS, INC.
Delaware | 000-51820 | 77-0567768 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
Alexza Pharmaceuticals, Inc. |
||||
2091 Stierlin Court |
94043 | |||
Mountain View, California |
||||
(Address of principal executive offices) |
(Zip Code) |
Registrants telephone number, including area code: (650) 944-7000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 7 Regulation FD
Item 7.01. | Regulation FD Disclosure. |
On September 7, 2010, Alexza Pharmaceuticals, Inc. issued a press release announcing that it will
participate in two investor conferences in September 2010 at The New York Palace hotel in New York,
New York, including (i) the Rodman & Renshaw Annual Global Investment Conference on Tuesday,
September 14, 2010 at 3:40 p.m. ET and (ii) the JMP Securities Healthcare Conference on Monday,
September 27, 2010 at 2:00 p.m. ET. The press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information presented under this Item
7.01 and attached as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing.
Section 9 Financial Statements and Exhibits
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit Number | Description | |||
99.1 | Press Release titled Alexza Pharmaceuticals to Present at
Upcoming Healthcare Conferences dated September 7, 2010. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Alexza Pharmaceuticals, Inc. |
||||
Date: September 7, 2010 | By: | /s/ Thomas B. King | ||
Thomas B. King | ||||
President and Chief Executive Officer | ||||
INDEX TO EXHIBITS
Exhibit Number | Description | |||
99.1 | Press Release titled Alexza Pharmaceuticals to Present at
Upcoming Healthcare Conferences dated September 7, 2010. |